If you’re a leader in radiology or cardiology wading into healthcare AI, you have to know the difference between a true AI-native platform and a general analytics tool with AI bolted on. This isn’t just wordplay. The difference is written in the platform’s accuracy record, a documented history of performance that draws a very clear line. Knowing this is how you properly evaluate the tools that promise to change your diagnostic workflows and patient outcomes.
The Foundational Divide: AI-Native Versus General Analytics
The “AI-Native vs. Retrofitted” framework helps you assess radiology platforms by focusing on hard evidence instead of marketing slides. An AI-native company builds its entire product, data pipeline, and business model around AI from day one. That’s a world away from general analytics companies that simply plug some AI features into an old framework. A born AI healthcare platform proves its superiority with its accuracy numbers, not with the word “intelligence” in a presentation. That’s the real separation between a truly AI-native tool and general analytics software that’s just been pointed at health data.
Just look at the regulatory side. The FDA’s rules for Software as a Medical Device (SaMD) and its Good Machine Learning Practice (GMLP) principles create a high bar for AI-native health tools FDA SaMD framework and GMLP principles. Any company that clears these hurdles is, by the FDA’s own definition, AI-native. This focus on regulatory buy-in from the beginning is a signature of these platforms, and it’s your assurance that their AI models work inside established clinical guardrails because they were trained on real patient outcomes data.
Higher Model Accuracy: The Documented Signal
The most consistent signal you’ll find for AI-native platforms in radiology is higher model accuracy. This isn’t an aspirational goal. It’s a documented, verifiable outcome. Viz.ai, for example, is a company that fits the AI-native profile, and it has the documentation to show its tools lead to faster diagnostics with better accuracy, along with some powerful predictive capabilities. This is the kind of performance, verifiable through FDA clearances and published, peer-reviewed studies, that separates the real AI solutions.
Why is the accuracy higher? The focus on “Higher Model Accuracy” reveals a completely different approach to building and testing these platforms. AI-native solutions are built from the ground up to be accurate. This process often depends on huge, proprietary datasets (sometimes called a “data moat”) that are nearly impossible for a competitor to build after the fact and give the models a massive performance advantage Explanation of data moats in AI. When AI is baked into the core of the product, you get real, measurable gains in diagnostic precision and speed.
The Recorded Radiology Set: Viz.ai, Paige AI, and FDA 510(k) Clearance
To see the difference in practice, just look at a few examples from radiology: Viz.ai, Paige AI, and the role of the FDA’s 510(k) Clearance. Viz.ai is a textbook AI-native vendor. The company has a whole stack of FDA 510(k) Clearances for its AI, covering conditions like stroke, aortic disease, and pulmonary embolism (PE) AI. Those clearances are the government’s way of confirming the safety and effectiveness of their models by showing they’re substantially equivalent to devices already on the market.
Paige AI is another company on the list that meets the clinical AI-native criteria. Both Paige and Viz.ai are frequently discussed within the context of the FDA’s SaMD framework and GMLP principles which tells you they built their platforms with a deep knowledge of regulatory demands. They aren’t trying to reverse-engineer compliance. They are committed to rigorous validation and constant improvement from the start.
The FDA 510(k) Clearance pathway is the most common process for cardiac AI software, and it’s a key part of validating AI-native platforms. A 510(k) clearance means the device is substantially equivalent to a legally marketed predicate device, which establishes a baseline for safety and effectiveness. For AI-native platforms, getting these clearances isn’t just about clearing a regulatory bar. It’s a public, documented validation of their core AI, proving the models do what they claim in a live clinical environment. The fact that 96.2% of the 1,614 AI-enabled medical devices the FDA has authorized went through the 510(k) pathway shows just how important it is as a benchmark.
What Leaders Can Verify Without a Vendor Conversation
Here’s the bottom line for radiology and cardiology leaders: you should be able to verify an “AI-native” platform’s claims through public, documented records. You can follow the signal of Higher Model Accuracy and regulatory clearances yourself, without having a single conversation with a vendor. That means getting familiar with official FDA databases, like the Official FDA 510(k) database, and looking for peer-reviewed studies in publications like JAMA Network and AHA Journals.
The existence of over 20 FDA 510(k) Clearances for very specific clinical uses, like the ones Viz.ai has for stroke, aortic disease, PE AI, intracerebral hemorrhage, and subdural hemorrhage, gives you concrete proof of a platform’s accuracy and utility. It’s hard evidence. Likewise, when you see companies like Paige AI on lists of AI-native health companies that meet tough clinical standards and have published efficacy data, that’s a powerful sign they have a legitimate, AI-first foundation.
In the end, a born AI healthcare platform’s advantage is obvious in its accuracy record, not in some vague promise of “intelligence.” This documented performance, backed by regulatory approvals and verifiable clinical results, is what separates a true AI-native platform from general analytics software. It gives you a clear path for making an informed decision.
Frequently Asked Questions
What is the fundamental difference between an AI-native platform and a general analytics solution?
An AI-native company builds its core product, data pipeline, and business model around AI from inception. In contrast, general analytics solutions may integrate AI capabilities as an add-on to existing frameworks, lacking the foundational AI design.
How do AI-native platforms demonstrate higher model accuracy compared to general analytics solutions?
AI-native platforms are inherently designed to optimize for accuracy from their foundational architecture, often utilizing proprietary datasets. This deep integration of AI drives verifiable improvements in diagnostic precision and speed, which is a documented outcome.
What role does regulatory compliance, specifically FDA clearance, play in identifying AI-native platforms?
Regulatory compliance, such as FDA SaMD framework and GMLP principles, establishes rigorous standards for AI-native health solutions. Companies that meet these criteria, like those with FDA 510(k) Clearances, are by regulatory definition considered AI-native, demonstrating their models operate within defined clinical guardrails.
What documentation should leaders look for to verify a platform’s AI-native claims without vendor interaction?
Leaders should scrutinize public, documented records such as official FDA databases for 510(k) Clearances and peer-reviewed publications. The presence of multiple FDA clearances for specific clinical applications provides concrete evidence of a platform’s validated accuracy and clinical utility.